Skip to main content
SpringerLink
Log in

Autoimmune and Connective Tissue Disease in Skin of Color

  • Chapter
  • First Online:
Dermatoanthropology of Ethnic Skin and Hair

Abstract

The manifestations of autoimmune and connective tissue disease in skin of color populations is multifaceted and unique. Incidence of diseases, such as lupus, morphea, scleroderma, dermatomyositis, and sarcoidosis in ethnic populations has been show to differ in several ways from their Caucasian counterparts. Furthermore, in ethnic groups, disease burden at presentation, severity of disease, prognosis, and disease-specific mortality have been shown to differ between ethnicities, as well when compared to Caucasian populations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Durosaro O, et al. Incidence of cutaneous lupus erythematosus, 1965–2005: a population-based study. Arch Dermatol. 2009;145(3):249–53.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Osio-Salido E, Manapat-Reyes H. Epidemiology of systemic lupus erythematosus in Asia. Lupus. 2010;19(12):1365–73.

    Article  CAS  PubMed  Google Scholar 

  3. Rees F, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis. 2016;75(1):136–41.

    Article  PubMed  Google Scholar 

  4. Flower C, et al. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012;64(8):1151–8.

    Google Scholar 

  5. Borba EF, et al. Clinical and immunological features of 888 Brazilian systemic lupus patients from a monocentric cohort: comparison with other populations. Lupus. 2013;22(7):744–9.

    Article  CAS  PubMed  Google Scholar 

  6. Castano-Rodriguez N, et al. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmun Rev. 2008;7(4):322–30.

    Article  CAS  PubMed  Google Scholar 

  7. Alarcon GS, et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum. 1998;41(7):1173–80.

    Article  CAS  PubMed  Google Scholar 

  8. Molineros JE, et al. Admixture in Hispanic Americans: its impact on ITGAM association and implications for admixture mapping in SLE. Genes Immun. 2009;10(5):539–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lee YH, Ji JD, Song GG. Fcgamma receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Lupus. 2009;18(8):727–34.

    Article  CAS  PubMed  Google Scholar 

  10. Yuan H, et al. Meta analysis on the association between FcgammaRIIa-R/H131 polymorphisms and systemic lupus erythematosus. Mol Biol Rep. 2009;36(5):1053–8.

    Article  CAS  PubMed  Google Scholar 

  11. Li LH, et al. Role of the Fcgamma receptor IIIA-V/F158 polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Scand J Rheumatol. 2010;39(2):148–54.

    Article  PubMed  Google Scholar 

  12. Chai HC, et al. Insight into gene polymorphisms involved in toll-like receptor/interferon signalling pathways for systemic lupus erythematosus in South East Asia. J Immunol Res. 2014;2014:529167.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Katkam SK, et al. Association of CTLA4 exon-1 polymorphism with the tumor necrosis factor-alpha in the risk of systemic lupus erythematosus among South Indians. Hum Immunol. 2016;77(2):158–64.

    Article  CAS  PubMed  Google Scholar 

  14. Chua KH, et al. Association between PDCD1 gene polymorphisms and risk of systemic lupus erythematosus in three main ethnic groups of the Malaysian population. Int J Mol Sci. 2015;16(5):9794–803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

    Article  CAS  PubMed  Google Scholar 

  16. Petit A, Dadzie OE. Multisystemic diseases and ethnicity: a focus on lupus erythematosus, systemic sclerosis, sarcoidosis and Behcet disease. Br J Dermatol. 2013;169(Suppl 3):1–10.

    Article  PubMed  Google Scholar 

  17. Fabbri P, et al. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol. 2003;4(7):449–65.

    Article  PubMed  Google Scholar 

  18. Tebbe B, et al. Markers in cutaneous lupus erythematosus indicating systemic involvement. A multicenter study on 296 patients. Acta Derm Venereol. 1997;77(4):305–8.

    CAS  PubMed  Google Scholar 

  19. Deng JS, Sontheimer RD, Gilliam JN. Relationships between antinuclear and anti-Ro/SS-A antibodies in subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 1984;11(3):494–9.

    Article  CAS  PubMed  Google Scholar 

  20. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;48–49:14–9.

    Article  PubMed  CAS  Google Scholar 

  21. Arrico L, et al. Ocular complications in cutaneous lupus erythematosus: a systematic review with a meta-analysis of reported cases. J Ophthalmol. 2015;2015:254260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Wollina U, et al. Lupus erythematosus-associated red lunula. J Am Acad Dermatol. 1999;41(3 Pt 1):419–21.

    Article  CAS  PubMed  Google Scholar 

  23. Al-Refu K, Goodfield M. Hair follicle stem cells in the pathogenesis of the scarring process in cutaneous lupus erythematosus. Autoimmun Rev. 2009;8(6):474–7.

    Article  PubMed  Google Scholar 

  24. Fernandes MS, et al. Discoid lupus erythematosus with squamous cell carcinoma: a case report and review of the literature in Indian patients. Lupus. 2015;24(14):1562–6.

    Article  CAS  PubMed  Google Scholar 

  25. Keith WD, et al. Squamous cell carcinoma arising in lesions of discoid lupus erythematosus in black persons. Arch Dermatol. 1980;116(3):315–7.

    Article  CAS  PubMed  Google Scholar 

  26. Baltaci M, Fritsch P. Histologic features of cutaneous lupus erythematosus. Autoimmun Rev. 2009;8(6):467–73.

    Article  PubMed  Google Scholar 

  27. Harrist TJ, Mihm MC Jr. The specificity and clinical usefulness of the lupus band test. Arthritis Rheum. 1980;23(4):479–90.

    Article  CAS  PubMed  Google Scholar 

  28. Cozzani E, et al. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis. 2014;2014:321359.

    PubMed  PubMed Central  Google Scholar 

  29. Jakes RW, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159–68.

    Article  Google Scholar 

  30. Serdula MK, Rhoads GG. Frequency of systemic lupus erythematosus in different ethnic groups in Hawaii. Arthritis Rheum. 1979;22(4):328–33.

    Article  CAS  PubMed  Google Scholar 

  31. Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. Ann Rheum Dis. 1994;53(10):675–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Samanta A, et al. High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus. Ann Rheum Dis. 1991;50(7):490–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Deligny C, et al. Pure cutaneous lupus erythematosus in a population of African descent in French Guiana: a retrospective population-based description. Lupus. 2012;21(13):1467–71.

    Article  CAS  PubMed  Google Scholar 

  34. Molokhia M, et al. Systemic lupus erythematosus in migrants from west Africa compared with Afro-Caribbean people in the UK. Lancet. 2001;357(9266):1414–5.

    Article  CAS  PubMed  Google Scholar 

  35. Bajaj DR, Devrajani BR, Matlani BL. Discoid lupus erythematosus: a profile. J Coll Physicians Surg Pak. 2010;20(6):361–4.

    PubMed  Google Scholar 

  36. Johnson SR, et al. Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. J Rheumatol. 2006;33(10):1990–5.

    PubMed  Google Scholar 

  37. Stoll T, Seifert B, Isenberg DA. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35(3):248–54.

    Article  CAS  PubMed  Google Scholar 

  38. Patel M, et al. The prevalence and incidence of biopsy-proven lupus nephritis in the UK: evidence of an ethnic gradient. Arthritis Rheum. 2006;54(9):2963–9.

    Article  PubMed  Google Scholar 

  39. Alarcon GS, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus in minority populations: nature vs. nurture. Lupus. 1999;8(3):197–209.

    Article  CAS  PubMed  Google Scholar 

  40. Pons-Estel BA, et al. The GLADEL multinational Latin American prospective inception cohort of 1214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among “Hispanics”. Medicine (Baltimore). 2004;83(1):1–17.

    Article  Google Scholar 

  41. Tan TC, et al. Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol. 2012;39(4):759–69.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Scalzi LV, Hollenbeak CS, Wang L. Racial disparities in age at time of cardiovascular events and cardiovascular-related death in patients with systemic lupus erythematosus. Arthritis Rheum. 2010;62(9):2767–75.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Wadee S, Tikly M, Hopley M. Causes and predictors of death in South Africans with systemic lupus erythematosus. Rheumatology (Oxford). 2007;46(9):1487–91.

    Article  CAS  Google Scholar 

  44. Gómez-Puerta JA, Barbhaiya M, Guan H, Feldman CH, Alarcón GS, Costenbader KH. Racial/Ethnic variation in all-cause mortality among United States medicaid recipients with systemic lupus erythematosus: a Hispanic and asian paradox. Arthrit Rheumatol. 2015;67(3):752–60.

    Google Scholar 

  45. Wang Z, et al. Long-term survival and death causes of systemic lupus erythematosus in China: a systemic review of observational studies. Medicine (Baltimore). 2015;94(17):e794.

    Article  CAS  Google Scholar 

  46. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, as well as causes of death. Arthritis Rheum. 1990;33(1):37–48.

    Article  CAS  PubMed  Google Scholar 

  47. Korbet SM, et al. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18(1):244–54.

    Article  PubMed  Google Scholar 

  48. Kaslow RA. High rate of death caused by systemic lupus erythematosus among U. S. residents of Asian descent. Arthritis Rheum. 1982;25(4):414–8.

    Article  CAS  PubMed  Google Scholar 

  49. Agbai ON, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol. 2014;70(4):748–62.

    Article  PubMed  Google Scholar 

  50. Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol. 1998;39(6):899–920; quiz 921–2.

    Google Scholar 

  51. Marmor MF, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94.

    Article  PubMed  Google Scholar 

  52. Pons-Estel GJ, et al. Lupus in Latin-American patients: lessons from the GLADEL cohort. Lupus. 2015;24(6):536–45.

    Article  CAS  PubMed  Google Scholar 

  53. Isenberg D, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–40.

    Article  Google Scholar 

  54. Arnett FC, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001;44(6):1359–62.

    Article  CAS  PubMed  Google Scholar 

  55. Mayes MD, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–55.

    Article  PubMed  Google Scholar 

  56. Laing TJ, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40(4):734–42.

    Article  CAS  PubMed  Google Scholar 

  57. Steen V, et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64(9):2986–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Steen VD, et al. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963–1982. Arthritis Rheum. 1997;40(3):441–5.

    Article  CAS  PubMed  Google Scholar 

  59. Arnett FC, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum. 1996;39(8):1362–70.

    Article  CAS  PubMed  Google Scholar 

  60. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360(19):1989–2003.

    Article  CAS  PubMed  Google Scholar 

  61. Falanga V, Zhou L, Yufit T. Low oxygen tension stimulates collagen synthesis and COL1A1 transcription through the action of TGF-beta1. J Cell Physiol. 2002;191(1):42–50.

    Article  CAS  PubMed  Google Scholar 

  62. Silver RM, et al. Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol. 2012;24(6):642–8.

    Article  PubMed  PubMed Central  Google Scholar 

  63. He D, et al. Association of the HLA-DRB1 with scleroderma in Chinese population. PLoS ONE. 2014;9(9):e106939.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  64. Tikly M, et al. Human leukocyte antigen class II associations with systemic sclerosis in South Africans. Tissue Antigens. 2004;63(5):487–90.

    Article  CAS  PubMed  Google Scholar 

  65. Beretta L, et al. Analysis of class II human leucocyte antigens in Italian and Spanish systemic sclerosis. Rheumatology (Oxford). 2012;51(1):52–9.

    Article  CAS  Google Scholar 

  66. Arnett FC, et al. Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2010;69(5):822–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Pope JE, Johnson SR. New classification criteria for systemic sclerosis (scleroderma). Rheum Dis Clin North Am. 2015;41(3):383–98.

    Article  PubMed  Google Scholar 

  68. Bolognia JL. Dermatology, vol. 3, 3rd ed. Elsevier/Saunders; 2012.

    Google Scholar 

  69. Schinke S, Riemekasten G. Systemic sclerosis. Dtsch Med Wochenschr. 2016;141(8):550–6.

    Article  PubMed  Google Scholar 

  70. Reveille JD, et al. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001;30(5):332–46.

    Article  CAS  PubMed  Google Scholar 

  71. Dadzie OE. Ushering in a new era for studying human cutaneous diversity. Br J Dermatol. 2013;169 Suppl 3:iii–iv.

    Google Scholar 

  72. Grassi W, et al. Microvascular involvement in systemic sclerosis: capillaroscopic findings. Semin Arthritis Rheum. 2001;30(6):397–402.

    Article  CAS  PubMed  Google Scholar 

  73. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP, Varga J. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15053.

    Google Scholar 

  74. Shah AA, Wigley FM. My approach to the treatment of scleroderma. Mayo Clin Proc. 2013;88(4):377–93.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Mendoza F, Derk CT. Systemic sclerosis mortality in the United States: 1999–2002 implications for patient care. J Clin Rheumatol. 2007;13(4):187–92.

    Article  PubMed  Google Scholar 

  76. Nietert PJ, et al. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005;32(10):1888–92.

    PubMed  Google Scholar 

  77. Nietert PJ, et al. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006;33(2):263–8.

    PubMed  Google Scholar 

  78. Persa OD, Moinzadeh P, Hunzelmann N. Systemic sclerosis. Current classification and diagnosis of organ involvement. Hautarzt. 2015;66(8):599–603.

    Article  CAS  PubMed  Google Scholar 

  79. Gladue H, et al. Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum. 2014;43(4):536–41.

    Article  PubMed  Google Scholar 

  80. Mayes MD, et al. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. Arthritis Rheum. 2004;50(2):553–7.

    Article  CAS  PubMed  Google Scholar 

  81. Pope JE, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–8.

    Article  CAS  PubMed  Google Scholar 

  82. Kreuter A, Gambichler T. UV-A1 phototherapy for sclerotic skin diseases: implications for optimizing patient selection and management. Arch Dermatol. 2008;144(7):912–6.

    Article  PubMed  Google Scholar 

  83. Chatterjee S. Management of Raynaud’s phenomenon in the patient with connective tissue disease. Curr Treat Options Cardiovasc Med. 2010;12(2):185–204.

    Article  PubMed  Google Scholar 

  84. Emmanuel A. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol. 2016;13(8):461–72.

    Article  CAS  PubMed  Google Scholar 

  85. Iaccarino L, et al. The clinical features, diagnosis and classification of dermatomyositis. J Autoimmun. 2014;48–49:122–7.

    Article  PubMed  CAS  Google Scholar 

  86. Hochberg MC. Epidemiology of polymyositis/dermatomyositis. Mt Sinai J Med. 1988;55(6):447–52.

    CAS  PubMed  Google Scholar 

  87. Oddis CV, et al. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963–1982. J Rheumatol. 1990;17(10):1329–34.

    CAS  PubMed  Google Scholar 

  88. Reed AM, Stirling JD. Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995;44(3):131–5.

    Article  CAS  PubMed  Google Scholar 

  89. Bolognia JL, Jorizzo JL, Schaffer JV. Dermatology, vol. 1, 3rd ed. Philadelphia, PA: Elsevier Saunders; 2012.

    Google Scholar 

  90. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol. 2012;24(6):602–8.

    Article  CAS  PubMed  Google Scholar 

  91. Fujimoto M, et al. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28(6):636–44.

    Article  CAS  PubMed  Google Scholar 

  92. Fiorentino D, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol. 2011;65(1):25–34.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Trallero-Araguas E, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64(2):523–32.

    Article  CAS  PubMed  Google Scholar 

  94. Fiorentino DF, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013;65(11):2954–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Satoh M, et al. Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study. Arthritis Res Ther. 2011;13(3):R73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. O’Hanlon TP, et al. HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum. 2006;54(11):3670–81.

    Article  PubMed  CAS  Google Scholar 

  97. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.

    Article  CAS  PubMed  Google Scholar 

  98. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403–7.

    Article  CAS  PubMed  Google Scholar 

  99. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–82.

    Article  CAS  PubMed  Google Scholar 

  100. Hoogendijk JE, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14(5):337–45.

    Article  PubMed  Google Scholar 

  101. Medsger TA Jr, Dawson WN, Masi AT Jr. The epidemiology of polymyositis. Am J Med. 1970;48(6):715–23.

    Article  PubMed  Google Scholar 

  102. Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep. 2010;12(3):192–7.

    Article  PubMed  Google Scholar 

  103. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36.

    Article  PubMed  Google Scholar 

  104. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;372(18):1734–47.

    Article  PubMed  Google Scholar 

  105. Ee HL, Ng PP, Tan SH. Exacerbation of amyopathic dermatomyositis in orientals: a high alert for nasopharyngeal carcinoma. Australas J Dermatol. 2004;45(1):77–8.

    Article  PubMed  Google Scholar 

  106. Schwarz HA, et al. Muscle biopsy in polymyositis and dermatomyositis: a clinicopathological study. Ann Rheum Dis. 1980;39(5):500–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008;59(1):99–112.

    Article  PubMed  Google Scholar 

  108. Constantin T, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary–clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006;39(3):223–32.

    Article  CAS  PubMed  Google Scholar 

  109. Huber AM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43(3):541–9.

    Article  CAS  PubMed  Google Scholar 

  110. Drake LA, et al. Guidelines of care for dermatomyositis. American Academy of Dermatology. J Am Acad Dermatol. 1996;34(5 Pt 1):824–9.

    Google Scholar 

  111. Phillips BA, et al. Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve. 1998;21(12):1668–72.

    Article  CAS  PubMed  Google Scholar 

  112. Kurtzman DJ, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944–5.

    Article  PubMed  Google Scholar 

  113. Fett N, Werth VP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2011;64(2):217–28; quiz 229–30.

    Google Scholar 

  114. Christen-Zaech S, et al. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–96.

    Article  PubMed  Google Scholar 

  115. Leitenberger JJ, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol. 2009;145(5):545–50.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Peterson LS, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960–1993. J Rheumatol. 1997;24(1):73–80.

    CAS  PubMed  Google Scholar 

  117. Pequet MS, et al. Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients. Br J Dermatol. 2014;170(4):895–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol. 2006;18(6):606–13.

    Article  PubMed  Google Scholar 

  119. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol. 2007;56(2):257–63.

    Article  PubMed  Google Scholar 

  120. Chak G, Wang HZ, Feldon SE. Coup de sabre presenting with worsening diplopia and enophthalmos. Ophthalmic Plast Reconstr Surg. 2011;27(4):e97–8.

    Article  Google Scholar 

  121. Fett N, Werth VP. Update on morphea: part II. Outcome measures and treatment. J Am Acad Dermatol. 2011;64(2)231–42; quiz 243–4.

    Google Scholar 

  122. Zwischenberger BA, Jacobe HT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol. 2011;65(5):925–41.

    Article  CAS  PubMed  Google Scholar 

  123. Zulian F, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006.

    Article  CAS  PubMed  Google Scholar 

  124. Foley PJ, et al. Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis. Am J Respir Cell Mol Biol. 2001;25(3):272–7.

    Article  CAS  PubMed  Google Scholar 

  125. Levin AM, et al. Association of HLA-DRB1 with sarcoidosis susceptibility and progression in African Americans. Am J Respir Cell Mol Biol. 2015;53(2):206–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Rossman MD, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet. 2003;73(4):720–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Rybicki BA, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145(3):234–41.

    Article  CAS  PubMed  Google Scholar 

  128. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci. 1976;278:321–34.

    Article  CAS  PubMed  Google Scholar 

  129. Edmondstone WM, Wilson AG. Sarcoidosis in Caucasians, Blacks and Asians in London. Br J Dis Chest. 1985;79(1):27–36.

    Article  CAS  PubMed  Google Scholar 

  130. Morimoto T, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J. 2008;31(2):372–9.

    Article  CAS  PubMed  Google Scholar 

  131. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361(9363):1111–8.

    Article  CAS  PubMed  Google Scholar 

  132. Guidry C, et al. Imaging of Sarcoidosis: A Contemporary Review. Radiol Clin North Am. 2016;54(3):519–34.

    Article  PubMed  Google Scholar 

  133. Wanat KA, Rosenbach M. Cutaneous Sarcoidosis. Clin Chest Med. 2015;36(4):685–702.

    Article  PubMed  Google Scholar 

  134. Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in Asians: a report of 25 patients from Singapore. Clin Exp Dermatol. 2005;30(2):120–4.

    Article  PubMed  Google Scholar 

  135. Elgart ML. Cutaneous sarcoidosis: definitions and types of lesions. Clin Dermatol. 1986;4(4):35–45.

    Article  CAS  PubMed  Google Scholar 

  136. Mana J, et al. Granulomatous cutaneous sarcoidosis: diagnosis, relationship to systemic disease, prognosis and treatment. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30(4):268–81.

    PubMed  Google Scholar 

  137. Pasadhika S, Rosenbaum JT. Ocular Sarcoidosis. Clin Chest Med. 2015;36(4):669–83.

    Article  PubMed  PubMed Central  Google Scholar 

  138. Albertini JG, Tyler W, Miller OF 3rd. Ulcerative sarcoidosis. Case report and review of the literature. Arch Dermatol. 1997;133(2):215–9.

    Article  CAS  PubMed  Google Scholar 

  139. Heath CR, David J, Taylor SC. Sarcoidosis: are there differences in your skin of color patients? J Am Acad Dermatol. 2012;66(1):121.e1–14.

    Google Scholar 

  140. Pietinalho A, et al. The frequency of sarcoidosis in Finland and Hokkaido. Japan. A comparative epidemiological study. Sarcoidosis. 1995;12(1):61–7.

    CAS  PubMed  Google Scholar 

  141. Lynch JP 3rd, et al. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med. 2014;35(3):372–90.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Iwai K, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis. 1994;11(1):26–31.

    CAS  PubMed  Google Scholar 

  143. Haimovic A, et al. Sarcoidosis: a comprehensive review and update for the dermatologist: part II. Extracutaneous disease. J Am Acad Dermatol. 2012;66(5):719.e1–10; quiz 729–30.

    Google Scholar 

  144. Soto-Gomez N, Peters JI, Nambiar AM. Diagnosis and Management of Sarcoidosis. Am Fam Physician. 2016;93(10):840–8.

    PubMed  Google Scholar 

  145. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160(2):736–55.

    Article  Google Scholar 

  146. Fernandez-Faith E, McDonnell J. Cutaneous sarcoidosis: differential diagnosis. Clin Dermatol. 2007;25(3):276–87.

    Article  PubMed  Google Scholar 

  147. Heinle R, Chang C. Diagnostic criteria for sarcoidosis. Autoimmun Rev. 2014;13(4–5):383–7.

    Article  CAS  PubMed  Google Scholar 

  148. Sekhri V, et al. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7(4):546–54.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Gerke AK. Morbidity and mortality in sarcoidosis. Curr Opin Pulm Med. 2014;20(5):472–8.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Mirsaeidi M, et al. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438–49.

    Article  PubMed  Google Scholar 

  151. Swigris JJ, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. 2011;183(11):1524–30.

    Article  PubMed  PubMed Central  Google Scholar 

  152. Haimovic A, et al. Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol. 2012;66(5):699 e1–18; quiz 717–8.

    Google Scholar 

  153. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064–71.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Boston University Medical Center, 609 Albany Street, Boston, MA, 02118, USA

    Babu Singh, Scott Walter, Daniel J. Callaghan III. & Christina Lam

  2. Boston University School of Medicine, 609 Albany St., Boston, MA, 02118, USA

    Jennifer Paek

Authors
  1. Babu Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scott Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel J. Callaghan III.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jennifer Paek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christina Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Lam .

Editor information

Editors and Affiliations

  1. Department of Dermatology, Center for Ethnic Skin, Boston University, Boston, Massachusetts, USA

    Neelam A. Vashi

  2. University of California, San Francisco, San Francisco, California, USA

    Howard I. Maibach

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Singh, B., Walter, S., Callaghan, D.J., Paek, J., Lam, C. (2017). Autoimmune and Connective Tissue Disease in Skin of Color. In: Vashi, N., Maibach, H. (eds) Dermatoanthropology of Ethnic Skin and Hair. Springer, Cham. https://doi.org/10.1007/978-3-319-53961-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53961-4_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53960-7

  • Online ISBN: 978-3-319-53961-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation